

**Form 51-102F3
Material Change Report**

Item 1 Name and Address of Company

Cabbay Holdings Corp.
(the "Company")
Suite 1735 Two Bentall Centre
555 Burrard St.
Vancouver, BC V7X1M9

Item 2 - Date of Material Change

October 16, 2020

Item 3 News Release

A news releases was issued and disseminated on October 16, 2020 and filed on SEDAR (www.sedar.com).

Item 4 Summary of Material Change

The Company has appointed John Buckle P. Geo to the Board of Directors.

Item 5 Full Description of Material Change

See attached news release at Schedule "A"

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

The following senior officer of the Company is knowledgeable about the material change and this report:

Name and Position: Douglas Unwin, President & CEO

Email: doug.unwin@cabbayholdings.com

Phone: 604.762.5355

Item 9 Date of Report

October 16, 2020

JOHN BUCKLE P. GEO. JOINS CABBAY BOARD OF DIRECTORS

VANCOUVER, BC, CANADA – October 16, 2020– Cabbay Holdings Corp. (the "Company") welcomes John Buckle P. Geo. to the board of directors.

Mr. Buckle, P.Geo., has been involved in the discovery of a variety of mineral deposits. Mr. Buckle's insight and interpretation of airborne geophysical data pinpointed the kimberlites that led to the Ekati and Snap Lake diamond mines in Canada's Northwest Territories. He identified the Eastern Deeps airborne anomaly of the giant Voisey's Bay nickel mine. For Desert Sun in Brazil, his interpretation of ground IP geophysical data discovered new resources that led to the re-opening of the mined-out Jacobina gold deposit, now in production by Yamana. The discovery holes at the rich El Domo VHMS deposit were spotted by Mr. Buckle. He re-processed and interpreted 40-year-old data that resulted in the targeting of Doubleview Ventures gold rich porphyry copper project.

About Cabbay Holdings Corp.

The Company's subsidiary Alta-Sun Samson Holdings Corp. ("Alta-Sun") has acquired technology for the development of a potential treatment for cytokine storms in disease such as COVID-19, Sepsis, Influenza and Acute Respiratory Distress Syndrome as well as other infectious and non-infectious disease. In addition, Alta-Sun owns a sublingual formulation of sildenafil citrate for erectile dysfunction and pulmonary arterial hypertension that is ready for further clinical trials.

For further information, please contact:

Douglas H. Unwin,
President & CEO
(604) 762-5355
doug.unwin@cabbayholdings.com.

FORWARD LOOKING STATEMENTS

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.